Lifecore Biomedical, Inc. LFCR

Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% PremiumLifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in Cash at ClosingBoth Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance MilestonesStockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash and CV

CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the CPHI Global Conference. The conference will take place October 6-8, 2026, in Milan, Italy. Details regarding Lifecore’s participation are as follows: CPHI Global Conference Details: Lifecore leaders, including Mark DaFonseca, chief commercial of

-- Significant New Program Positioned to Become One of Lifecore’s Largest Contracts -- -- Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Drug Product -- -- Program Expected to Contribute to 2028 Commercial Revenues -- CHASKA, Minn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced it has signed a new agreement t

Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, […]

Moby summary of Lifecore Biomedical, Inc.'s Q2 2026 earnings call

Despite a 6.2% revenue dip, Lifecore secures nine new programs and reaffirms 2026 guidance, positioning for a 200% demand surge from its largest customer by 2028.

-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization -- Conference Call Today at 8:00am ET CHASKA, Minn., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the second quarter and six months ended June 30, 20

Webcast Scheduled for Wednesday, August 5 at 8:00 a.m. EasternCHASKA, Minn., July 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens. At 8:00 a.m. Eastern Time that day, members of Lifecore’s senior management team will ho

--Technology Transfer Agreement for Regenerative Medicine Late-Stage Development Program-- --Two Additional Agreements Supporting Early-Stage Programs Including Formulation and Development for a Global Medical Technology Company -- -- All Programs are Additive to Lifecore’s High-Value Pipeline and Expected to Contribute to 2028 Revenue -- CHASKA, Minn., July 28, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and

CHASKA, Minn., July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on July 13, 2026, Lifecore granted a restricted stock unit (“RSU”) award with respect to 3,500 shares of its common stock under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) to a newly hired employee of Lifecore. The RSU award was granted pursuant t

Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing Water Capital returning approximately 39.8% net of all fees and expenses, bringing the YTD return to approximately 33.6% net. […]

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Lifecore Biomedical, Inc. (NASDAQ:LFCR) is one of the best low-priced pharma stocks on this list. TheFly reported on June 16 that Barrington increased its price target on LFCR to $6.50 from $6.00 while reaffirming an Outperform rating on the shares. The […]

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product-- --Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months-- CHASKA, Minn., June 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced it has signed a new agreement with a global pharmaceutical company. Under the terms of the agreement, Lifecore

Lifecore Biomedical’s analyst narrative has been updated, with a fair value estimate holding at US$6.67, while several Street price targets now cluster closer to the US$5 to US$5.50 range. That shift aligns with recent commentary that balances confidence in the long term opportunity with more cautious views on the timing of commercial ramps and the updated FY26 outlook. As you read on, you will see how these moving parts shape the evolving story and what to watch to stay in sync with it. Wall...

-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn., June 02, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a manufacturing services agreement with a leading provider of ophthalmic disease